Your browser doesn't support javascript.
loading
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin, Esther; Garmendia, Irati; Lozano, Teresa; Serrano, Diego; Senent, Yaiza; Redrado, Miriam; Villalba, Maria; De Andrea, Carlos E; Exposito, Francisco; Ajona, Daniel; Ortiz-Espinosa, Sergio; Remirez, Ana; Bertolo, Cristina; Sainz, Cristina; Garcia-Pedrero, Juana; Pio, Ruben; Lasarte, Juan; Agorreta, Jackeline; Montuenga, Luis M; Calvo, Alfonso.
Afiliación
  • Redin E; IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
  • Garmendia I; CIBERONC, ISCIII, Madrid, Spain.
  • Lozano T; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain.
  • Serrano D; IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
  • Senent Y; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain.
  • Redrado M; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
  • Villalba M; IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
  • De Andrea CE; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain.
  • Exposito F; IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
  • Ajona D; IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
  • Ortiz-Espinosa S; Department of Pathology, University Clinic of Navarra, Pamplona, Spain.
  • Remirez A; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain.
  • Bertolo C; Department of Pathology, University Clinic of Navarra, Pamplona, Spain.
  • Sainz C; IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
  • Garcia-Pedrero J; CIBERONC, ISCIII, Madrid, Spain.
  • Pio R; Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain.
  • Lasarte J; IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
  • Agorreta J; CIBERONC, ISCIII, Madrid, Spain.
  • Montuenga LM; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
  • Calvo A; IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
J Immunother Cancer ; 9(3)2021 03.
Article en En | MEDLINE | ID: mdl-33658304
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfocitos Infiltrantes de Tumor / Linfocitos T Reguladores / Carcinoma de Pulmón de Células no Pequeñas / Inhibidores de Proteínas Quinasas / Proliferación Celular / Proteínas Proto-Oncogénicas c-yes / Receptor de Muerte Celular Programada 1 / Dasatinib / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: J Immunother Cancer Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfocitos Infiltrantes de Tumor / Linfocitos T Reguladores / Carcinoma de Pulmón de Células no Pequeñas / Inhibidores de Proteínas Quinasas / Proliferación Celular / Proteínas Proto-Oncogénicas c-yes / Receptor de Muerte Celular Programada 1 / Dasatinib / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: J Immunother Cancer Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido